2Pascual LA, Roque FM, Urrutia CG, et al. Systematic review of megestrol acetate in the treatment of anorexiacachexia s yndrome. Pain Symptom Manage, 2004,27 (4) : 360 -369.
3Munshi A, Pandey MB,Durga T, et al. Weight loss during radiotherapy for head and neck malignancies:what factors impact it. Cancer,2003,47 (2) :136-140.
6Deutsch J. Kolhouse JF. Assessment of gastrointestinal funotion and response to megesterol acetate in subjects with gastrointestinal cancers and weight loss. Support Care Cancer,200d, 12 (7) :503-510.
8Lofgren LWa llberg B. Wilking N, et al. Tamoxifen and megestrol acetate for postmeno pausal breast cancer, diver ging effects on liver proteins,androgens, and gluco corticoids. Med Oncol,2004 ;21 ( 4 ) : 309 - 318.
4Simons JP,Schols AM,Hoefnagels JM,et al.Effects of medroxyprogesterone acetate on food intake,body cpmposition,and restingenergy expenditure in patients with advanced,nonhormone-sensitivecancer.a randomized,placebo-controlled trial[J].Cancer,1998,82(3):553～560.
5Yamshita JI,Ogawa M.Breast medroxygesterone acetate and cancer cachexia:interleukin-6 involvement[J].cancer,2000,84(2):130～135.
6Mantovni G,Maccio A,Madeddu C,et al.Immunotherapy (recombinant interleukin 2),hormone therapy(medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of respondersto previous hemotherapy[J].Int J Oncol,2001,18(2):383～891.
7Nishimura R,Nagao k,Miyayama H,et al.An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer[J].Oncology,2000.59(2):166～173.
8Beli E,Tattersall M,Lumley T,et al.Improved quality of life with megestrol acetate in patients with endocrine in sensitive advanced cancer.Ann Oncol,1997,8:277-283.
9Pannutil F,Cstrocchi E.Hight doses of MPA in oncoiog patients doubts and certainties.Semin Oncol,1998,1(Suppl 1):76-78.
